Device Trial Radar · NCT02042404
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Last checked: Nov 20, 2026Latest source record: Feb 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 2014
Primary completion
Jan 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- EarLens CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 22, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The EarLens System is an assistive hearing device that is intended to provide amplification for the treatment of patients with sensorineural hearing impairment. The purpose of this multi-center definitive study is to assess the safety and efficacy of the EarLens System for subjects with bilateral mild to severe sensorineural hearing impairments wearing the fully activated system in their daily lives for a 4 month period of time. This study is designed to support US and International marketing applications to commercialize the EarLens System. The main efficacy hypothesis is that the EarLens System will be shown to improve speech understanding in quiet.
Conditions
- Hearing Impairment
Interventions
Sound amplification provided via EarLens System.Device
The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Aided Word Recognition Scores (WRS) When Compared to the Baseline Unaided Condition.Time frame: Baseline and 30 days
- Audiometric Safety as Shown by no Hearing Change Pre and Post TreatmentTime frame: Baseline and 120 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
EarLens Corporation
Menlo Park, California
Camino Ear Nose and Throat Clinic
San Jose, California
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.